Phase I-II Pilot Study to Evaluate the Immune-mediated Effects of an Autologous Tumor-derived Heat Shock Protein-peptide Complex 96 (HSPPC-96) Combined With Ipilimumab in Patients With Therapeutically Unresectable Stage III or Stage IV Malignant Melanoma
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 发起方
- 试验地点
- 1
- 主要终点
- All enrolled patients who receive at least one dose of study drug (HSPPC-96) will be evaluated for safety. (adverse events)
研究概览
简要总结
The purpose of this research study is to see if the combination of HSPPC-96 and ipilimumab is safe and effective in the treatment of advanced melanoma. HSPPC-96 is an investigational vaccine created from tissue from the patient's tumor. The vaccine is designed to capture the cancer's "fingerprint." Injection of the vaccine may cause the patient's immune system to recognize and attack any cells with the specific cancer fingerprint. Ipilimumab is a drug approved by the FDA for the treatment of metastatic melanoma that boosts immune response.
详细描述
This is a randomized, open label, single-center, phase I-II trial to determine the safety, feasibility and immunogenicity of combination treatment of HSPPC-96 and ipilimumab in patients with therapeutically unresectable Stage III or Stage IV malignant melanoma.
The main purpose of this study is to assess whether the administration of the combination of ipilimumab and HSPPC-96 is safe. The rationale for combining the two treatments resides in their respective roles on the immune system as described below and based on the clinical experience collected so far. HSPPC-96 is able to initiate a tumor specific immune response that ipilimumab could theoretically amplify by blocking a checkpoint that naturally down-regulates T cells.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pre-surgery Inclusion criteria:
- •Signed informed consent
- •≥ 18 years of age
- •Stage III or Stage IV melanoma according to TNM staging criteria/AJCC version 7 determined by PET/MRI/CT scan
- •ECOG score 0 or 1
- •Life expectancy ≥6 months
- •Candidate for surgical resection with viable melanoma tissue to ascertain ≥ 7 grams of viable cancer tissue (in aggregate), which is equivalent to a ≥ 2 cm lesion on CT/MRI or clinical examination
- •Adequate cardiac function (≤ NYHA class II)
- •Adequate bone marrow function, including: absolute granulocyte count (ANC) ≥ 1,500x106/L, absolute lymphocyte count (ALC) ≥ 500/mm3, platelets count ≥100,000 x 106/mm
- •Adequate liver function including: serum glutamic oxaloacetic transaminases/aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x the upper limit of institutional normal (IULNs), bilirubin ≤ 1.5 mg/dL or 25 µmol/L (SI units). Adequate renal function: BUN and Serum creatinine of ≤ 1.5 mg/dL or 130 µmol/L (SI units)
- •Female subjects of childbearing potential and fertile males must agree to use adequate contraception during the course of the study. Adequate contraception includes condoms with contraceptive foam; oral, implantable or injectable contraceptives; contraceptive patch; intrauterine device; diaphragm with spermicidal gel; or a sexual partner who is surgically sterilized or postmenopausal.
- •Post-surgery Inclusion Criteria (must be completed within 4 weeks of surgery)
- •Histologically and clinically confirmed Stage III and/or Stage IV malignant melanoma according to TNM Staging Criteria/AJCC version 7 confirmed by PET/CT scan
- •Measurable disease for target lesion clinical and radiological monitoring
- •ECOG score 0 or 1
- •Adequate cardiac function (≤ NYHA class II)
- •Adequate bone marrow function, liver, and renal function
- •≥ 6 doses of vaccine for clinical use
排除标准
- •Pre-Surgery Exclusion Criteria:
- •Primary mucosal or primary ocular melanomas
- •Other malignancies treated within the last five years, except in situ cervix carcinoma or non-melanoma skin cancer
- •Primary or secondary immunodeficiency (including immunosuppressive disease, or systemic use of corticosteroids or other immunosuppressive medications)
- •Patients with history of HIV1 and 2, HTLV-1, HBV or active HCV.
- •Patients with history of connective tissue disorders
- •Prior ipilimumab or melanoma vaccine therapy
- •Prior therapy with IL-2
- •Prior chemotherapy, small molecule targeted therapy, interferon within 3 months prior to enrollment
- •Prior investigational products administration within 4 weeks prior to enrollment
- •Prior splenectomy
- •Symptomatic CNS metastases or spinal cord compression
- •Uncontrolled infection or other serious medical illnesses
- •Any medical conditions that, in the opinion of the investigator, would preclude use of ipilimumab, including ipilimumab hypersensitivity
- •Women who are pregnant or breast-feeding
- •Concurrent participation in investigational trials
- •Post-surgery Exclusion Criteria (must be completed within 4 weeks of surgery):
- •Emergence of contraindicated clinical condition
研究组 & 干预措施
ipilimumab + HSPPC-96
- Ipilimumab is administered intravenously at a dose of 3 mg/kg one day (a minimum of 12 hours and not more than 48 hours) before HSPPC-96 every 21-25 days for a total of 4 cycles.
- HSPPC-96 is administered at a dose of 25 μg by intradermal injection always 12 - 48 hours following ipilimumab on a weekly basis for the first 4 weeks and then every 3 weeks always 12 - 48 hours after ipilimumab.
- Length of Treatment: 4 cycles of ipilimumab and at least 6 cycles of HSPPC-96 up to 12 doses.
- Booster doses of HSPCC-96 following 6 administrations on subsequent cycles will be administered every 21-23 days according to availability of vaccine.
干预措施: ipilimumab (Drug)
ipilimumab + HSPPC-96
- Ipilimumab is administered intravenously at a dose of 3 mg/kg one day (a minimum of 12 hours and not more than 48 hours) before HSPPC-96 every 21-25 days for a total of 4 cycles.
- HSPPC-96 is administered at a dose of 25 μg by intradermal injection always 12 - 48 hours following ipilimumab on a weekly basis for the first 4 weeks and then every 3 weeks always 12 - 48 hours after ipilimumab.
- Length of Treatment: 4 cycles of ipilimumab and at least 6 cycles of HSPPC-96 up to 12 doses.
- Booster doses of HSPCC-96 following 6 administrations on subsequent cycles will be administered every 21-23 days according to availability of vaccine.
干预措施: HSPPC-96 (Drug)
结局指标
主要结局
All enrolled patients who receive at least one dose of study drug (HSPPC-96) will be evaluated for safety. (adverse events)
时间窗: 2 years
AEs will be coded by system organ class and preferred term using MedDRA. AEs will be summarized using descriptive statistics. Descriptive statistics will contain the number and percentage of patients who experience at least 1 AE, AEs related to study treatment, SAEs, SAEs related to study treatment, grade 3, 4 or 5 AEs, and grade 3, 4 or 5 AEs related to study treatment. In addition, the number and percentage of patients who discontinue treatment for any reason, including discontinuation due to an AE, will be provided together with the number and percentage of patients who die.
• To assess immunological response by surrogate markers of immune response and modulation of tumor cellular microenvironment
时间窗: 2 years
All enrolled patients who receive at least one full cycle of treatment and have a baseline and at least one post treatment biological specimen available (tissue and/or blood) will be evaluated for immune response.
次要结局
- Objective Response Rate (ORR)(tumor evaluations every 12 weeks or until the date of first documented progression or death, whichever came first, assessed up to 24 months)
- Progression Free Survival (PFS)(tumor evaluations every 12 weeks or until the date of first documented progression or death, whichever came first, assessed up to 24 months)
研究者
Rabih Said
Assistant Professor, Department of Internal Medicine, Division of Oncology
The University of Texas Health Science Center, Houston